LAS VEGAS, Aug. 26, 2020
Rising prevalence, launch of new therpaies, incremental healthcare spending, heightened R&D, improved reimbursement policies and a better understanding of the disease are the major Vernal keratoconjunctivitis market drivers.
LAS VEGAS, Aug. 26, 2020 /PRNewswire/ -- DelveInsight has launched a new report 'Vernal keratoconjunctivitis - Market Insights, Epidemiology, and Market Forecast-2030' in its repository.
Request for Free Sample Pages of the Report: https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market
A relatively rare form of ocular allergy, Vernal keratoconjunctivitis (VKC) can result into severe visual complications. VKC is an IgE- and T-cell meditated disease, causing a chronic inflammation with non-specific, barely understood hypersensitivity responses. The ocular allergy is characterized by conjunctival hyperemia, itching, photophobia, and tearing, with symptoms usually more severe during spring and summer.
Vernal keratoconjunctivitis prevalence is relatively higher in dry and hot climates (Mediterranean areas, Central and West Africa, and South America), however, it has a wide geographical distribution.
The Vernal keratoconjunctivitis market report proffers in depth epidemiological segmentation analysis for the study period 2017-30, the epidemiology for this disease is segmented as following in the report:
Treatment of Vernal keratoconjunctivitis requires multiple approaches that include conservative measures and pharmacologic treatment. The present Vernal keratoconjunctivitis treatment market comprises mast cell stabilizers, vasoconstrictors, antihistamines, 'dual-acting' agents (with antihistaminic and mast cell stabilizing properties), nonsteroidal anti-inflammatory drugs (NSAIDs), topical corticosteroids, cyclosporine, tacrolimus, and immunosuppressive drugs.
The treatment is only supportive in nature and is not that effective. However, with the advancement of technology and a better understanding of the pathophysiology of the disease several novel emerging therapies are in the horizon to advance Vernal keratoconjunctivitis market.
However, there exists no defined or standard care for the VKC patients. VKC treatment algorithm requires to be tailored as per patients 'requirements with proper understanding of the duration of the treatment regimen and a careful monitoring for the corneal complications.
Vernal keratoconjunctivitis Marketed Drugs
As per DelveInsight, global Vernal keratoconjunctivitis market is expected to change in the study period 2017–2030. With the launch of therapies in the VKC pipeline such as Verkazia (Santen), AK002 (Allakos), Bertilimumab/iCo-008 (iCo Therapeutics), and Nomacopan (Akari Therapeutics) in the US, the Vernal keratoconjunctivitis market size is expected to grow in the forecasted period 2020–30. Out of the emerging therapies, the most anticipated product to get launched and occupy the major chunk of Vernal keratoconjunctivitis market share is the AK002 (Allakos).
Furthermore, there are other companies who have their drugs in the early pre-clinical phases of development such as including Postbiotica and Sylentis, hence the launch of their therapies is expected further after in the forecasted period.
Vernal keratoconjunctivitis Pipeline Drugs
With only limited treatment option available in the market, there are lucrative opportunities for the pharma players in the Vernal keratoconjunctivitis market to dominate and grow. Moreover, the current pipeline appears weak, which further becomes a significant inviting factor for the companies to explore the VKC market. However, poor diagnostic modalities, easy availability of OTC medications, generics and strict reimbursement policies are expected to obstruct and slow down the Vernal keratoconjunctivitis market growth.
Identify Key Trends of Vernal keratoconjunctivitis Market: https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market
Scope of the Report
Reason to purchase
Table of Contents
Executive Summary of Vernal keratoconjunctivitis
Vernal keratoconjunctivitis Market Overview at a Glance
Vernal keratoconjunctivitis: Disease Background and Overview
Vernal keratoconjunctivitis Cases Reports
Vernal keratoconjunctivitis Epidemiology and Patient Population
The United States Vernal keratoconjunctivitis Epidemiology
EU-5 Country-wise Vernal keratoconjunctivitis Epidemiology
Japan Vernal keratoconjunctivitis Epidemiology
MEA Vernal keratoconjunctivitis Epidemiology
China Vernal keratoconjunctivitis Epidemiology
Russia Vernal keratoconjunctivitis Epidemiology
Current Vernal keratoconjunctivitis Treatment Practices
Unmet Needs in Vernal keratoconjunctivitis Market
Vernal keratoconjunctivitis Marketed Therapies
Vernal keratoconjunctivitis Emerging Therapies
Vernal keratoconjunctivitis: Seven Major Market Analysis
7MM Vernal keratoconjunctivitis Market Size
United States Vernal keratoconjunctivitis Market Size
EU-5 Vernal keratoconjunctivitis Market Size
Japan Vernal keratoconjunctivitis Market Size
MEA Vernal keratoconjunctivitis Market Size
China Vernal keratoconjunctivitis Market Size
Russia Vernal keratoconjunctivitis Market Size
Vernal keratoconjunctivitis Market Drivers
Vernal keratoconjunctivitis Market Barriers
Market Access and Reimbursement of Vernal keratoconjunctivitis Therapies
SWOT Analysis of Vernal keratoconjunctivitis
Request a WebEx Walkthrough of the Report: https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market
Vernal Keratoconjunctivitis - Epidemiology Forecast to 2030
DelveInsight's 'Vernal Keratoconjunctivitis - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Vernal Keratoconjunctivitis epidemiology in the 7MM - the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, MEA (Saudi Arabia and Egypt) and Russia.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.